FK 506 dosage in human organ transplantation.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Transplantation Proceedings

• Publication date

  1990-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 1689890PMCID PMC2903883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of FK 506 on renal function after liver transplantation.

  1990cited by this paper
• Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.

  1990cited by this paper
• Pharmacokinetics of FK 506: preclinical and clinical studies.

  1990cited by this paper
• FK 506 for liver, kidney, and pancreas transplantation.

  1989cited by this paper
• Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.

  1987cited by this paper

• Solid Organ Transplantation

  2011cites this paper
• RadioreceptorAssay for QuantifyingFK-506 Immunosuppressantin Whole Blood

  2004influential citation
• Malononitrilamid 715 als Immunsuppressivum im Modell der heterotopen Herztransplantation in der Maus

  2001cites this paper
• Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells.

  1998cites this paper
• Tacrolimus (FK 506) overdose: a report of five cases.

  1997cites this paper
• Maintenance Immunosuppressive Drug Therapy and Potential Major Complications

  1996cites this paper
• Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation.

  1995cites this paper
• Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits.

  1994cites this paper
• Adult respiratory distress syndrome secondary to end-stage liver disease-successful outcome following liver transplantation.

  1993cites this paper
• [FK506: an immunosuppressor for the '90's?].

  1993cites this paper
• Recent advances in hepatic transplantation at the University of Pittsburgh.

  1993cites this paper
• FK506 conversion for intractable rejection of the liver allograft

  1993cites this paper
• EXPERIENCE WITH FK506 IN LIVING‐RELATED LIVER TRANSPLANTATION

  1993cites this paper
• A COMPARISON OF RENAL FUNCTION IN CYCLOSPORINE- AND FK‐506-TREATED PATIENTS AFTER PRIMARY ORTHOTOPIC LIVER TRANSPLANTATION

  1993cites this paper
• The immunosuppressive effect of FK 506 on canine lung transplantation.

  1992cites this paper
• Radioreceptor AssayforQuantifying FK-506Immunosuppressant inWholeBlood

  1992cites this paper
• Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation.

  1991cites this paper
• Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line.

  1991cites this paper
• Effect of FK-506 on replication of human cytomegalovirus in vitro.

  1991cites this paper
• Nursing implications of immunosuppression in transplantation.

  1991cites this paper
• Transplantation's Newest Weapon FK 506

  1991cites this paper
• FK 506 rescue therapy in liver transplantation: outcome and complications.

  1991cites this paper
• FK 506 rescue therapy for refractory acute rejection in five liver recipients.

  1991cites this paper
• Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

  1991cites this paper
• Liver transplantation: Results, advances and problems

  1990cites this paper
• The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.

  1990cites this paper